Introduction {#s1}
============

Genetic discoveries have provided critical insights into potential mechanisms of Alzheimer's disease (AD), the most common neurodegenerative disease. Mutations in *APP*, *PSEN1*, or *PSEN2* cause early-onset, autosomal dominantly inherited AD, but are quite rare. Several more common genetic variants that increase AD risk to differing degrees have been identified. Among these, variants near *BIN1* have particularly high population attributable risk, because the risk allele is highly prevalent (\~40% allele frequency for the index SNP, rs6733839) and has a relatively large effect size (odds ratio: 1.20; 95% confidence interval: 1.17--1.23) ([@bib41]).

*BIN1* was first linked to AD in early genome-wide associated studies (GWAS) ([@bib29]; [@bib75]) and remains second only to *APOE* in genome-wide significance in the recent meta-analysis of 94,437 individuals by the International Genomics of Alzheimer's Disease Project ([@bib41]). This association has been replicated in datasets with subjects from diverse genetic backgrounds ([@bib10]; [@bib31]; [@bib35]; [@bib42]; [@bib45]; [@bib52]; [@bib59]; [@bib82]; [@bib38]; [@bib12]; [@bib43]; [@bib49]; [@bib56]; [@bib66]; [@bib48]; [@bib22]; [@bib67]; [@bib81]). Further, unbiased epigenetic analyses have provided independent evidence linking *BIN1* to AD pathogenesis in several epigenome-wide association studies examining DNA methylation patterns in brain tissue from AD patients, in which *BIN1* again emerged as a top hit ([@bib17]; [@bib14]; [@bib83]). This association was also observed in tissue from preclinical AD patients, indicating that changes in *BIN1* methylation occur early in disease ([@bib17]; [@bib14]). Also, associations between *BIN1* methylation and AD are independent of genetic variants identified in GWAS, providing an orthogonal line of evidence for BIN1's involvement in AD. Importantly, *BIN1* variants have been linked to earlier age of onset ([@bib60]). In addition to GWAS reports examining polymorphisms associated with AD diagnosis by clinical criteria, other studies have examined genetic risk factors for AD neuropathology. BIN1 was significantly associated with both amyloid plaque and neurofibrillary tangle pathologies, strengthening the association with AD ([@bib2]). While these unbiased screens have convincingly implicated *BIN1* in AD pathogenesis, the mechanisms underlying the association are not yet known, and many important questions about how *BIN1* contributes to AD remain.

One of the main limitations is an incomplete understanding of BIN1's normal function in the brain. Its structure suggests that a key role may involve protein trafficking at the membrane, since all BIN1 isoforms contain an N-terminal BAR (BIN1/Amphiphysin/RVS167) domain that mediates membrane binding and curvature, plus a C-terminal SH3 domain that mediates protein--protein interactions, including with Tau ([@bib12]; [@bib76]). The larger, neuron-specific isoforms also contain a clathrin-AP2 binding (CLAP) domain likely involved in endocytosis ([@bib18]).

The *BIN1* variants associated with AD do not alter the coding sequence of BIN1 but are rather concentrated in a presumed regulatory region upstream of the promoter. Although BIN1 is ubiquitously expressed throughout the body, levels are highest in the brain and muscle ([@bib9]), and its most critical role is in the heart, as homozygous deletion of murine *Bin1* causes early lethality due to severe ventricular cardiomyopathy ([@bib58]). Canonically, BIN1 plays a role in protein trafficking and endocytosis, specifically trafficking L-type voltage gated calcium channels (LVGCCs) in cardiac myocytes to the membrane to strengthen calcium signaling ([@bib33]). However, the function BIN1 plays in neurons remains much less clear.

In this study, we addressed BIN1's role in neurons by expressing the predominant neuronal BIN1 isoform (isoform 1) in primary hippocampal neuron cultures. Our studies revealed a role for BIN1 in regulating neuronal activity and a potential molecular mechanism involving its interactions with calcium channel subunits.

Results {#s2}
=======

Higher BIN1 induces network hyperexcitability {#s2-1}
---------------------------------------------

To begin studying the effects of altered BIN1 levels in neurons, we first used AAV to express the predominant neuronal isoform of human BIN in primary rat hippocampal neuronal cultures. We verified expression of BIN1 using an mKate2 fluorophore fused to the C-terminus. A construct encoding mKate2 alone was used as a control. We determined that BIN1 expression increased \~8--9-fold by immunocytochemistry and remained stable up to 3.5 weeks post transduction ([Figure 1A--C](#fig1){ref-type="fig"}). Higher BIN1 did not change neuronal morphology ([Figure 1B](#fig1){ref-type="fig"}), the total number of neurons per well ([Figure 1D--E](#fig1){ref-type="fig"}), nor the resting membrane potential (RMP) or input resistance (R~in~) of cultured neurons ([Table 1](#table1){ref-type="table"}), indicating no significant toxic or trophic effect of overexpressing BIN1 under these conditions.

###### Resting membrane potential (RMP) and input resistance (R~in~) in patched hippocampal neurons did not differ across untransduced, AAV-mKate2, and AAV-BIN1-mKate2 groups.

                       RMP, mV          R~in~, MΩ        N, Cells
  -------------------- ---------------- ---------------- ----------
  Untransduced         --60.43 ± 5.36   843.04 ± 55.11   4
  AAV-mKate2           --59.90 ± 3.70   834.83 ± 41.09   6
  AAV-BIN1-mKate2      --62.40 ± 2.24   790.18 ± 15.74   7
  One-way ANOVA, *p*   0.85             0.36             

![BIN1 increases action potential and burst frequency in primary hippocampal neurons cultured on microelectrode arrays (MEAs).\
(**A**) ICC experimental timeline: neurons were plated on day in vitro (DIV) 0, virally transduced on DIV 2, and immunostained at DIV 15, DIV 22, or DIV 27. (**B**) Representative images of primary hippocampal cultures: untransduced (left), AAV-mKate2 (center), or AAV-BIN1-mKate2 (right), showing Tau and BIN1 immunostaining at DIV 15 (top), DIV 22 (middle), or DIV 27 (bottom). Scale bar = 20 µm. (**C**) AAV-BIN1-mKate2 increased BIN1 levels \~ 8--9-fold in BIN1 group compared to BIN1 levels in untransduced or mKate2 groups (*n* = 2--6 fields of view per coverslip, 60x magnification, two-way ANOVA, BIN-DIV interaction p=0.1123, main effect of AAV-BIN1-mKate2 \*\*\*\*p\<0.0001, main effect of DIV p=0.6373, Tukey's multiple comparisons test: DIV 15:UnTD vs. DIV 15:AAV-BIN1-mKate2, \*\*\*\*p\<0.0001, DIV 22:UnTD vs. DIV 22:AAV-BIN1-mKate2, \*\*\*\*p\<0.0001, DIV 27:UnTD vs. DIV 27:AAV-BIN1-mKate2, \*\*\*\*p\<0.0001. (**D**) Representative images of primary hippocampal cultures at DIV 12: untransduced (left), AAV-mKate2 (center), or AAV-BIN1-mKate2 (right), showing NeuN immunostaining (top), mKate2 fluorescence (middle), or merge of both (bottom). Scale bar = 25 µm. (**E**) The total number of neurons per well did not change between untransduced, mKate2, or BIN1 groups (*n* = 6--7 coverslips, 10 × 10 fields of view per coverslip, 20x magnification, from two different primary neuron harvests, one-way ANOVA, p=0.5157). (**F**) MEA experimental timeline: neurons were plated on day in vitro (DIV) 0, virally transduced on DIV 2, and recorded on DIV 12. (**G**) Primary neuronal hippocampal cultures grown on an MEA plate. Scale bar = 50 µm. (**H**) Representative local field potential (LFP) traces. (**I**) Representative raster plots of firing activity from five different neurons per group. (**J**) BIN1 increased action potential frequency (*n* = 27--36 neurons per group from three different primary neuron harvests, normalized to the controls from each harvest, median frequency in controls = 388 mHz; unpaired Mann-Whitney U test; p=0.0233). (**K**) BIN1 increased burst firing frequency (*n* = 27--36 neurons per group from three different primary neuron harvests, normalized to the controls from each harvest, median frequency in controls = 11.7 mHz; unpaired Mann-Whitney U test; p=0.0020). (**L**) The total number of active neurons per well did not differ between mKate2 and BIN1 expressing groups (*n* = 9 MEA plates for each group from three different primary neuron harvests, unpaired Student's t test; p=0.346). All data are expressed as mean ± SEM, \*p\<0.05, \*\*p\<0.01, and \*\*\*\*p\<0.0001. All data are expressed as mean ± SEM.](elife-57354-fig1){#fig1}

We then recorded action potentials and burst firing in these neurons on multielectrode arrays (MEAs) after 10 days ([Figure 1F--G](#fig1){ref-type="fig"}). Local field potential (LFP) traces representing neuronal action potential and burst firing were recorded for 20 min then analyzed ([Figure 1H--I](#fig1){ref-type="fig"}). We found that higher BIN1 levels were associated with increased frequency of action potentials (2.3-fold, [Figure 1J](#fig1){ref-type="fig"}) and action potential bursts (2.1-fold, [Figure 1K](#fig1){ref-type="fig"}). There was no change in the total number of active neurons on MEAs ([Figure 1L](#fig1){ref-type="fig"}).

Higher BIN1 increases frequency of spontaneous excitatory and inhibitory synaptic transmission {#s2-2}
----------------------------------------------------------------------------------------------

Since higher BIN1 levels increased action potential and burst frequencies in the MEA recordings, we hypothesized that this would be associated with an increased frequency of spontaneous excitatory postsynaptic currents (sEPSCs). To test this, we used whole-cell voltage-clamp recordings from BIN1-transduced neurons at DIV 19--21 ([Figure 2A](#fig2){ref-type="fig"}), pharmacologically isolating sEPSCs using picrotoxin to block inhibitory GABA~A~R currents. ([Figure 2B](#fig2){ref-type="fig"}). Consistent with the increased action potential frequency observed in MEA recordings ([Figure 1E](#fig1){ref-type="fig"}), higher BIN1 levels were associated with dramatically increased sEPSC frequency (interevent interval decreased \>50%) ([Figure 2C](#fig2){ref-type="fig"}). sEPSC amplitudes differed by \<10% ([Figure 2D](#fig2){ref-type="fig"}).

![BIN1 increases both excitatory and inhibitory synaptic transmission.\
(**A**) Synaptic transmission recordings experimental timeline: neurons were plated on DIV 0, virally transduced on DIV 2, electrophysiologically recorded on DIV 19--21. (**B**) Representative traces of sEPSCs recorded from neurons transduced with mKate2 or BIN1. (**C**) BIN1 decreased mean sEPSC interevent interval (Kolmogorov-Smirnov test on cumulative distribution, \*\*\*\*p\<0.0001, KS D score: 0.1657; unpaired two-tailed Student's t-test on mean IEI, \*\*\*\*p\<0.0001). (**D**) BIN1 slightly decreased mean sEPSC amplitude unpaired (Kolmogorov-Smirnov test on cumulative distribution, \*\*\*\*p\<0.0001, KS D score: 0.1803; unpaired two-tailed Student's t-test on mean amplitude, \*\*\*p=0.0004) (*n* = 12--21 neurons per group from three different primary neuron harvests). (**E**) Representative images and quantification of NeuN and GAD67+ neurons in primary hippocampal cultures at DIV 12 (*n* = 255 GAD67+ neurons, *n* = 2342 NeuN+ neurons, from 10 randomly taken images per coverslip, 10 coverslips from two different primary neuron harvests.) Scale bar = 100 µm. (**F**) Representative traces of sIPSCs recorded from neurons transduced with mKate2 or BIN1. (**G**) BIN1 decreased mean sIPSC interevent interval (Kolmogorov-Smirnov test on cumulative distribution, \*\*\*\*p\<0.0001, KS D score: 0.06862; unpaired two-tailed Student's t-test on mean IEI, \*\*p=0.0035) (**H**) BIN1 decreased mean sIPSC amplitude (Kolmogorov-Smirnov test on cumulative distribution, \*\*\*\*p\<0.0001, KS D score: 0.1297; unpaired two-tailed Student's t-test on mean amplitude, \*\*\*\*p\<0.0001) (*n* = 11--16 neurons per group from three different primary neuron harvests). All data are expressed as mean ± SEM.](elife-57354-fig2){#fig2}

To investigate if this effect of higher BIN1 levels was selective for excitatory transmission, we next examined whether higher BIN1 expression had similar effects on spontaneous inhibitory postsynaptic currents (sIPSCs). We determined the proportion of GABAergic interneurons in our primary hippocampal cultures and found that 10% of the neurons were GAD67 positive ([Figure 2E](#fig2){ref-type="fig"}), consistent with prior work ([@bib3]). To determine the effect of higher BIN1 levels on inhibitory synaptic transmission from these neurons, we recorded pharmacologically isolated GABA~A~R-mediated sIPSCs using DNQX, APV, and nifedipine to block AMPARs, NMDARs, and L-type voltage-gated calcium channels (LVGCCs), respectively ([Figure 2F](#fig2){ref-type="fig"}). Similar to the effect on sEPSC frequency, higher BIN1 increased sIPSC frequency (decrease in interevent interval, [Figure 2G](#fig2){ref-type="fig"}). There was a coincident decrease in sIPSC amplitude ([Figure 2H](#fig2){ref-type="fig"}).

Overall, these findings suggest that higher BIN1 levels increase the frequency of both sEPSCs and sIPSCs in primary hippocampal cultures, agreeing with the increased action potential firing observed using MEAs ([Figure 1E--F](#fig1){ref-type="fig"}).

Higher BIN1 in mature neurons increases calcium influx {#s2-3}
------------------------------------------------------

Using AAVs requires transduction soon after plating (DIV 2) because of the time required for transgene expression, so some effects could be due to increasing BIN1 levels during early neuronal development. To dissociate the effect of higher BIN1 on network hyperexcitability from neuronal development, we transiently transfected primary hippocampal cultures at DIV 14, when neurons are more fully developed ([Figure 3A](#fig3){ref-type="fig"}). We co-transfected BIN1 constructs with the genetically encoded calcium indicator, GCaMP6f, which allows for single neuron calcium imaging in primary hippocampal cultures. We used two BIN1 constructs, both based on human isoform one tagged with the mKate2 fluorophore. In addition to the full-length BIN1 construct used in [Figures 1](#fig1){ref-type="fig"}--[2](#fig2){ref-type="fig"}, we also used a construct engineered to remove the BAR domain (ΔBAR), which is predicted to abolish BIN1 membrane localization, and thus likely its activity. As before, mKate2 alone was used as a control construct. Interestingly, the pattern of mKate2 distribution within the neurons was strikingly different across groups, as mKate2 and BIN1-ΔBAR exhibited diffuse localization throughout the soma, neurites, and nucleus, while wild-type BIN1 had a punctate distribution throughout the cytosol but was excluded from the nucleus ([Figure 3B](#fig3){ref-type="fig"}). These observations agree with BAR-domain dependent membrane localization of BIN1 found in other cell types ([@bib33]; [@bib64]).

![Higher BIN1 levels in mature neurons increase calcium influx in primary hippocampal neuronal cultures.\
(**A**) Calcium imaging experimental timeline: neurons were plated on DIV 0, co-transfected on DIV 14 with GCaMP6f calcium indicator and either BIN1-mKate2, BIN1-ΔBAR-mKate2, or mKate2 control construct, and recorded on DIV 21. *n* = 14--20 neurons per condition. (**B**) mKate2 fluorescence in primary transfected primary hippocampal neurons. BIN1-mKate2 fluorescence was punctate in transfected neurons. mKate2 and BIN-BAR-mKate2 fluorescence was diffuse and filled the neuron. (**C**) GCaMP fluorescence intensity, F, relative to the quiescent period between transients, F~0~. Neurons were classified as either active (with a range of activity levels indicated by the top and middle traces) or inactive (no calcium transients during the 8 min recording, bottom trace). (**D**) BIN1, but not BIN1-ΔBAR, increased the proportion of active neurons (Binomial test, \*\*p=0.0071). (**E**) BIN1, but not BIN1-ΔBAR, increased neuronal calcium influx measured as area under the curve (AUC; one-way ANOVA, p=0.0134; Dunnett's posthoc, \*p=0.0122). (**F**) BIN1, but not BIN1-ΔBAR, increased the number of calcium transients (one-way ANOVA, p=0.0144; Dunnett's posthoc, mKate2 vs BIN1-mKate2 adjusted \*p=0.0437). All data are expressed as mean ± SEM.](elife-57354-fig3){#fig3}

We monitored basal calcium activity of individual transfected neurons by imaging GCaMP fluorescence using laser scanning microscopy. We measured the change in somatic GCaMP fluorescence intensity relative to the quiescent period between transients (defined as F~0~) and classified neurons as either active (≥1 calcium transient) or inactive (no calcium transients) ([Figure 3C](#fig3){ref-type="fig"}).

About a third of neurons were inactive under control conditions ([Figure 3D](#fig3){ref-type="fig"}), consistent with prior studies ([@bib40]; [@bib46]). However, neurons expressing the full-length human BIN1 construct were almost never inactive ([Figure 3D](#fig3){ref-type="fig"}). As expected, the BIN1-ΔBAR construct was similar to controls ([Figure 3D](#fig3){ref-type="fig"}), indicating the importance of BIN1 membrane localization for the effect. Increasing BIN1 levels roughly doubled calcium influx as measured by both area under the curve ([Figure 3E](#fig3){ref-type="fig"}) and the number of calcium transients ([Figure 3F](#fig3){ref-type="fig"}).

BIN1 interacts with LVGCCs in neurons {#s2-4}
-------------------------------------

We were interested to find that the ability of BIN1 to increase neuronal activity was dependent on the presence of the BAR domain, which is critical for its membrane localization. One of BIN1's known functions outside of the brain is localizing LVGCCs to the membrane of cardiomyocyte T-tubules ([@bib33]; [@bib34]). Therefore, we asked if BIN1 interacts with LVGCCs in neurons and if increased interaction between BIN1 and LVGCCs could be a potential mechanism by which BIN1 increases neuronal activity.

To begin addressing this question, we first examined BIN1 interactions with LVGCC beta-1 subunits (LVGCC-β1), which reside on the inner face of the membrane and target LVGCCs to the membrane ([@bib8]). To determine whether BIN1 and LVGCC-β1 interact directly, we used proximity ligation assay (PLA), which allows quantification and visualization of protein-protein interactions in situ, producing a fluorescent punctum whenever the two antibody epitopes are within 40 nm (i.e., directly interacting or nearby in a complex). We detected endogenous BIN1--LVGCC-β1 interaction in neuronal soma and neurites of untransduced neurons ([Figure 4A](#fig4){ref-type="fig"}). If a BIN1-mediated effect on LVGCC's underlies the observed effects on neuronal activity, then AAV-BIN1 constructs should increase the interaction ([Figure 4B](#fig4){ref-type="fig"}). Transduction with BIN1-mKate2 substantially increased BIN1--LVGCC-β1 interaction, while transduction with the mKate2 control vector did not change endogenous interaction levels ([Figure 4C,D](#fig4){ref-type="fig"}).

![BIN1 interacts with LVGCC-β1 subunits in neurons.\
(**A**) Localization of endogenous BIN1, LVGCC-β1, and endogenous BIN1-LVGCC-β1 interaction detected by PLA. Scale bar = 10 µm. (**B**) Experimental timeline: neurons were plated on DIV 0, transduced with AAV-BIN1-mKate2 or AAV-mKate2 on DIV 2, and fixed and stained on DIV 19--21. (**C**) Representative images of mKate2 fluorescence, BIN1--LVGCC-β1 PLA puncta, and BIN1 ICC in primary hippocampal neurons. Scale bar = 10 µm. (**D**) BIN1--LVGCC-β1 interaction was increased by BIN1 (*n* = 3--4 coverslips per group, each with 5 fields of view averaged, from three different primary neurons harvests; one-way ANOVA, p\<0.0001; Endogenous vs. AAV-BIN1-mKate2 \*\*\*\*p=0.0001 by Dunnett's post-hoc). All data are expressed as mean ± SEM.](elife-57354-fig4){#fig4}

BIN1-LVGCC interaction is Tau-dependent {#s2-5}
---------------------------------------

Multiple studies have demonstrated that BIN1 directly interacts with Tau, both in vitro and in vivo ([@bib12]; [@bib44]; [@bib71]). This interaction between BIN1 and Tau is mediated by the SH3 domain of BIN1 and PxxP motifs in Tau's central proline-rich region. Interestingly, LVGCC-β1 also harbors an SH3 domain that could also interact with Tau. Thus, we hypothesized that the BIN1 interaction with LVGCC-β1 might be at least in part scaffolded by Tau ([Figure 5A](#fig5){ref-type="fig"}).

![Tau-dependent BIN1--LVGCC interaction.\
(**A**) Model of Tau-dependent BIN1--LVGCC interaction. BIN1's BAR domain localizes BIN1 to the plasma membrane, and PxxP motifs in Tau's central proline-rich domain interact with the SH3 domains of BIN1 and LVGCC- β1. (**B**) Tau interacts with both BIN1 and LVGCC-β1 SH3 domains detected by bioluminescence resonance energy transfer (BRET) (*n* = 28--164 wells, one-way ANOVA, \*\*\*\*p\<0.0001). (**C**) Experimental timeline of BIN1--LVGCC-β1 PLA: neurons were plated on DIV 0, transduced with AAV-BIN1-mKate2 or AAV-mKate2 on DIV 2, treated with Tau or scrambled ASO on DIV 7, and stained on DIV 14. (**D**) AAV-BIN1-mKate2 increased BIN1-LVGCC-β1 interaction, while Tau reduction with Tau ASO decreased BIN1--LVGCC-β1 interactions (*n* = 4--6 coverslips per group representing an average of 4--5 fields of view (FOV) per coverslip from three different neuronal harvests; Two-way ANOVA, main effect of Tau ASO \*\*p=0.0018, main effect of AAV-BIN1-mKate2 \*\*\*\*p\<0.0001). (**E**) We immunoprecipitated LVGCC-β1 followed by western blotting for LVGCC-β1, Tau, and BIN1 from cortical homogenates of wild-type and Tau KO mice. The amount of LVGCC-β1 immunoprecipitated did not differ between wild-type and Tau KO brains (*n* = 5--6 mice, 3.56 ± 0.04 months old, unpaired Student's t test; p=0.5105). However, the amount of BIN1 co-immunoprecipitated with LVGCC-β1 was decreased in Tau KO brains compared to wild-type litter mate controls (*n* = 5--6 mice, unpaired Student's t test; \*p=0.0157). All data are expressed as mean ± SEM.](elife-57354-fig5){#fig5}

We first used a live-cell bioluminescence resonance energy transfer (BRET) assay ([@bib16]) to determine if Tau interacts with the SH3 domains of both BIN1 and LVGCC-β1. We transfected CHO cells with Tau-mKate2 (acceptor) and either the BIN1 SH3 domain or LVGCC-β1 SH3 domain tagged with click beetle green (donor) ([Figure 5B](#fig5){ref-type="fig"}). Both Tau--BIN1 and Tau--LVGCC-β1 demonstrated BRET, indicating that Tau interacts with each of these SH3 domains ([Figure 5C](#fig5){ref-type="fig"}).

We then tested the hypothesis that Tau affects the BIN1--LVGCCβ1 interaction, using the BIN1--LVGCC-β1 PLA assay with and without pretreatment with Tau antisense oligonucleotide (ASO) ([Figure 5D](#fig5){ref-type="fig"}). We recently demonstrated that this ASO reduces Tau protein by about 50% under these conditions ([@bib70]). Tau reduction decreased BIN1--LVGCC-β1 interaction in primary hippocampal neurons, compared to neurons treated with a scrambled control ASO ([Figure 5E](#fig5){ref-type="fig"}), indicating that in cultured neurons the BIN1--LVGCC-β1 interaction is partially Tau-dependent.

Next, we determined if the BIN1--LVGCC-β1 interaction is also Tau-dependent in vivo. Using cortical brain lysates from wild-type and Tau knockout (Tau KO) mice, we immunoprecipitated LVGCC-β1 and blotted for BIN1. BIN1 co-immunoprecipitated with LVGCC-β1 from these brain lysates, and the BIN1--LVGCC-β1 complex was reduced in Tau KO brains, without any difference in LVGCC-β1 immunoprecipitation ([Figure 5F](#fig5){ref-type="fig"}). Taken together, these data indicate that the BIN1--LVGCC interaction is partially Tau-dependent both in vitro and in vivo.

Tau reduction prevents network hyperexcitability induced by higher BIN1 {#s2-6}
-----------------------------------------------------------------------

Tau reduction is protective in many models of AD and it reduces network hyperexcitability in many disease models, including AD and epilepsy models ([@bib15]; [@bib68]; [@bib32]; [@bib69]; [@bib20]; [@bib26]; [@bib51]). Thus, since Tau reduction decreases BIN1--LVGCC-β1 interaction in primary hippocampal neurons and brain homogenates, we asked whether Tau reduction attenuates network hyperexcitability induced by increased BIN1.

To do this, we utilized a 48-well MEA system to permit recordings from many neurons with in-plate controls for each experiment. We grew neurons on the MEA, transduced them with AAV-BIN1 or AAV-mKate2 control, applied Tau ASO or a scrambled ASO control, then recorded neuronal activity ([Figure 6A](#fig6){ref-type="fig"}). As in our initial experiments, these manipulations did not affect the number of active neurons ([Figure 6B](#fig6){ref-type="fig"}), and higher BIN1 levels increased neuronal firing in this system as well ([Figure 6C--D](#fig6){ref-type="fig"}). Tau reduction completely blocked the BIN1-induced increases in action potential frequency ([Figure 6E--F](#fig6){ref-type="fig"}) and bursting ([Figure 6G--H](#fig6){ref-type="fig"}). These results demonstrate that BIN1-induced network hyperexcitability is Tau-dependent and add to the body of work demonstrating beneficial effects of Tau reduction on limiting network hyperexcitability and AD-related dysfunction.

![Tau reduction prevents network hyperexcitability induced by BIN1.\
(**A**) MEA experimental timeline: neurons were plated on DIV 0, virally transduced on DIV 2, treated with Tau or scrambled ASO on DIV 5, and electrophysiologically recorded on DIV 12. (**B**) The number of active neurons was not different between groups (*n* = 6--8 coverslips per group from three different neuronal harvests; two-way ANOVA, main effect of Tau ASO p=0.9140, main effect of AAV-BIN1-mKate2 p=0.9026, interaction p=0.1101). (**C**) Representative LFP traces of MEA recordings. (**D**) Representative raster plots of MEA recordings. (**E**) Tau reduction prevented BIN1-induced network hyperexcitability as measured by mean action potential frequency (*n* = 159--230 neurons from 6 to 8 wells per group from three different neuronal harvests; two-way ANOVA, BIN-Tau interaction \*\*p=0.0073, main effect of Tau ASO p=0.0761, main effect of AAV-BIN1-mKate2 \*p=0.0130, Sidak's multiple comparisons test: UnTd:Scr ASO vs. BIN1-mKate2:Scr ASO \*\*\*p=0.0010). (**F**) Cumulative distribution of the mean action potential frequency (Kolmogorov-Smirnov test on cumulative distribution, UnTD-Scr ASO vs. BIN1-mKate2-Scr ASO \*\*p=0.0028). (**G**) Tau reduction prevented BIN1-induced network hyperexcitability as measured by mean burst frequency (*n* = 159--230 neurons from 6 to 8 wells per group from three different neuronal harvests; two-way ANOVA, BIN-Tau interaction \*\*\*p=0.0005, main effect of Tau ASO \*\*p=0.0066, main effect of AAV-BIN1-mKate2 p=0.2286, Sidak's multiple comparisons test: UnTd:Scr ASO vs. BIN1-mKate2:Scr ASO \*p=0.0227). (**H**) Cumulative distribution of the burst frequency (Kolmogorov-Smirnov test on cumulative distribution, UnTD-Scr ASO vs. BIN1-mKate2-Scr ASO, p=0.1107). All data are expressed as mean ± SEM.](elife-57354-fig6){#fig6}

Discussion {#s3}
==========

Genetic data indicate that BIN1 can play an important role in AD pathogenesis, but a major limitation is the relatively poor understanding of BIN1's function in the central nervous system. We found that expressing the predominant human BIN1 isoform in primary hippocampal cultures led to a Tau-dependent increase in neuronal activity leading to network hyperexcitability. Higher BIN1 levels increased the frequency of both spikes and bursts recorded with multielectrode arrays ([Figure 1](#fig1){ref-type="fig"}). Using patch-clamp recordings of neurons overexpressing BIN1, we observed increased frequency of both excitatory and inhibitory synaptic transmission ([Figure 2](#fig2){ref-type="fig"}). Similarly, elevating BIN1 levels also increased calcium spikes in neurons co-transfected with the calcium indicator GCaMP6f ([Figure 3](#fig3){ref-type="fig"}). To understand the potential mechanism of increased calcium influx, we explored potential interactions with LVGCCs, which contribute to BIN1 effects on cardiac excitability. BIN1 interacted with LVGCCs in neurons in a Tau-dependent manner, assessed by both proximity ligation assay in cultured neurons and co-immunoprecipitation from brain ([Figures 4](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}). Finally, using a high-content multielectrode array system, we showed that Tau reduction prevented network hyperexcitability induced by BIN1 ([Figure 6](#fig6){ref-type="fig"}). Together, these data show Tau-dependent regulation of neuronal activity by the Alzheimer's disease risk gene *BIN1* and generate new insights about the mechanistic role BIN1 may play in AD.

Increasing evidence supports the idea that changes in neuronal excitability may contribute to AD pathogenesis. Functional imaging studies reveal hyperactivation of many brain regions in AD patients ([@bib21]; [@bib28]). This is an early event in AD pathogenesis, seen in asymptomatic individuals at genetic risk for AD ([@bib4]; [@bib65]). In addition, childhood epilepsy can drive subsequent amyloid accumulation ([@bib37]). Furthermore, seizures are more frequent in AD patients than in age-matched controls ([@bib1]; [@bib63]; [@bib74]), and in the early stages of disease, even patients without overt seizures often have epileptiform activity on neurophysiological recordings ([@bib79]; [@bib80]). Even more importantly, late-onset unprovoked seizures in older veterans are associated with a 2-fold risk of developing dementia, likely a first sign of neurodegenerative disease ([@bib39]). Hyperexcitability is also seen in mouse models of AD, many of which have seizures (often nonconvulsive) and epileptiform spikes ([@bib62]; [@bib55]), excitation-inhibition imbalance in synaptic recordings ([@bib69]), and increased intrinsic neuronal excitability ([@bib6]).

Existing data are consistent with a potential role for BIN1 in controlling neuronal excitability. As a membrane scaffolding protein, BIN1 promotes T-tubule formation in skeletal muscles ([@bib78]). In cardiomyocytes, Bin1 traffics LVGCCs to T-tubules, allowing for proper T-tubule formation and excitation-contraction coupling ([@bib33]; [@bib34]). Genetic loss of Bin1 in cardiomyocytes decreases surface localization of LVGCCs to T-tubules and decreases LVGCC calcium transients ([@bib33]). In addition, acute knockdown of Bin1 in primary cortical neurons reduced calcium spikes in response to NMDA ([@bib54]). Similarly, a chronic genetic deletion of Bin1 in mice decreased mEPSCs frequency, suggesting an effect of Bin1 on synaptic transmission ([@bib19]). Complementary to these studies on effects of decreased Bin1 expression in mice, we found that increased human BIN1 expression increases synaptic transmission, neuronal activity, and calcium transients, and that BIN1 interacts with LVGCCs in neurons. Moreover, we found that higher BIN1 increases not only excitatory, but also inhibitory synaptic transmission. Human genetics also support a link between BIN1 and network hyperexcitability, as the risk allele of the rs744373 variant upstream of *BIN1*, which is linked to AD, is also associated with impaired memory in temporal lobe epilepsy patients ([@bib7]).

Further studies will be needed to elucidate the precise mechanisms by which BIN1 regulates neuronal firing, but our studies suggest an effect on surface trafficking of LVGCCs. While biophysical and pharmacological properties of LVGCCs are tightly controlled by the principal α1 subunit, the cytosolic auxiliary β subunit plays an essential role in trafficking of LVGCCs to the plasma membrane ([@bib8]). Our study revealed BIN1 interaction with these LVGCC β subunits in neurons ([Figures 4](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}), likely contributing to LVGCC neuronal surface localization. LVGCCs modulate neuronal firing ([@bib50]) and control both basal and bursting neuronal activity through somatic and dendritic Ca^2+^ transients ([@bib57]; [@bib50]). LVGCCs are also linked to neurodegeneration by carrying toxic amounts of Ca^2+^ through an increase of LVGCC activity, density, or exposure to β-amyloid peptides ([@bib11]).

Our findings suggest that the effects of BIN1 on neuronal excitability likely involve Tau. A variety of evidence has linked BIN1 to Tau in studies of AD. In AD patients, the *BIN1* risk variant, rs744373, is associated with increased Tau-PET levels, as well as reduced functional connectivity and impaired memory ([@bib84]; [@bib25]). The fact that BIN1 localizes in a complex with Tau ([Figures 4](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}; [@bib12]; [@bib85]; [@bib76]; [@bib5]; [@bib53]; [@bib44]) supports the hypothesis that BIN1--Tau interaction regulates neuronal excitability, as there is now abundant data that a key function of Tau is regulating neuronal excitability, particularly susceptibility to hyperexcitability. This includes the fact that Tau^+/--^ and Tau^--/--^ mice are resistant to epileptiform activity and seizures induced by excitotoxic agents ([@bib68]; [@bib36]; [@bib69]). Tau knockdown using ASOs also has excitoprotective effects against hyperexcitability in mice ([@bib20]), complemented by our finding of excitoprotective effects against BIN1-induced hyperexcitability ([Figure 6](#fig6){ref-type="fig"}).

The precise effects of AD-associated *BIN1* variants remains to be fully understood, but their effects are likely to be mediated through changes in expression levels since they do not affect the coding sequence. For example, the risk allele of the AD-associated rs744373 variant drives increased expression of BIN1 ([@bib7]). While another early report suggested increased BIN1 in AD ([@bib12]), subsequent reports suggest that variants may reduce BIN1 expression ([@bib27]; [@bib30]), and the effects may also differ between the neuronal and ubiquitous isoforms ([@bib18]). Ongoing studies will provide additional evidence about the directionality of *BIN1* variant effects on expression, but our findings are consistent with either increases or decreases in BIN1 contributing to network hyperexcitability in AD, since we found that higher BIN1 was associated with higher activity as a general effect in both excitatory and inhibitory neurons. That is, either increased BIN1 in excitatory neurons with corresponding increased excitatory activity, or reduced BIN1 in inhibitory neurons with corresponding reduced inhibition, could lead to network hyperexcitability. Further study will be required to better understand both the effects of AD-associated *BIN1* variants and the relative balance between excitatory and inhibitory neuron effects of BIN1. In addition, BIN1 expression changes in oligodendrocytes or microglia also warrant study for their potential roles in AD ([@bib18]; [@bib61]).

Our findings highlight the potential importance of Tau interactions with SH3 domain--containing proteins. We recently demonstrated that inhibiting Tau-SH3 interactions can reduce Aβ toxicity ([@bib70]), and it is notable that BIN1 joins a growing list of SH3 domain--containing proteins that interact with Tau and are implicated in AD. Tau may act as a scaffolding protein through BIN1 interactions mediating membrane localization ([Figure 5A](#fig5){ref-type="fig"}), promoting network hyperexcitability through its SH3-domain containing binding partners. This could be a critical role for Tau and explain how mislocalization of Tau in AD contributes to the increased network excitability seen in AD pathogenesis. This would be consistent with the finding that reducing endogenous Tau prevents network hyperexcitability and Aβ-induced dysfunction in AD models.

In summary, we have shown that BIN1 promotes neuronal firing in a Tau-dependent manner. These data contribute new insights into the neuronal functions of BIN1, with implications for our understanding of AD.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                            Designation         Source or\                                                       Identifiers                                                                      Additional\
  (species) or\                                                reference                                                                                                                                         information
  resource                                                                                                                                                                                                       
  ---------------------------------------- ------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------
  Gene (*Homo sapiens*)                    *BIN1*              NCBI                                                             Gene ID 274                                                                      

  Antibody                                 Anti-NeuN\          abcam                                                            Cat\# ab104225; RRID:[AB_10711153](https://scicrunch.org/resolver/AB_10711153)   ICC (1:500), Lot \#GR3321966-1
                                           Rabbit polyclonal                                                                                                                                                     

  Antibody                                 Anti-GAD67\         Millipore Sigma                                                  Cat\# MAB5406; RRID:[AB_2278725](https://scicrunch.org/resolver/AB_2278725)      ICC (1:500), Lot \#3015328
                                           Mouse monoclonal                                                                                                                                                      

  Antibody                                 Anti-BIN1\          Santa Cruz                                                       Cat\# sc-30099; RRID:[AB_2243399](https://scicrunch.org/resolver/AB_2243399)     ICC/PLA/IP (1:500), Lot \#K1605; H-100
                                           Rabbit polyclonal                                                                                                                                                     

  Antibody                                 Anti-LVGCC-β1\      abcam                                                            Cat\# ab85020; RRID:[AB_1861569](https://scicrunch.org/resolver/AB_1861569)      ICC/PLA/IP (1:1000), Lot \#413-8RR-52
                                           Mouse monoclonal                                                                                                                                                      

  Antibody                                 Anti-Tau\           DAKO                                                             Cat\# A0024; RRID:[AB_10013724](https://scicrunch.org/resolver/AB_10013724)      ICC/IP (1:1000), Lot \#20031827
                                           Rabbit polyclonal                                                                                                                                                     

  Antibody                                 Anti-BIN1\          Santa Cruz                                                       Cat\# sc-13575; RRID:[AB_626753](https://scicrunch.org/resolver/AB_626753)       ICC/IP (1:1000), Lot \#L3014; 99D
                                           Mouse monoclonal                                                                                                                                                      

  Cell line\                               Primary neuron      Charles River                                                                                                                                     Fresh from E19 albino Sprague Dawley rats
  (*Rattus norvegicus*)                                                                                                                                                                                          

  Genetic reagent                          AAV-BIN1-mKate2     UPenn Vector Core                                                                                                                                 AAV2

  Genetic reagent                          AAV-mKate2          UPenn Vector Core                                                                                                                                 AAV2

  Sequence-based reagent                   Tau ASO             PMID:[23904623](https://www.ncbi.nlm.nih.gov/pubmed/23904623)\                                                                                    5-ATCACTGATTTTGAAGTCCC-3
                                                               IDT                                                                                                                                               

  Sequence-based reagent                   Scrambled ASO       PMID:[23904623](https://www.ncbi.nlm.nih.gov/pubmed/23904623)\                                                                                    5-CCTTCCCTGAAGGTTCCTCC-3
                                                               IDT                                                                                                                                               

  Commercial assay, kit                    Duolink PLA kit     Millipore Sigma                                                  Cat\#s DUO92014; DUO92002; DUO92004                                              

  Transfected construct                    GCaMP6f             Addgene                                                          RRID:[Addgene_40755](https://scicrunch.org/resolver/Addgene_40755)               

  Transfected construct                    mKate2              PMID:[25156556](https://www.ncbi.nlm.nih.gov/pubmed/25156556)\   Cat\# FP184                                                                      Actin was removed from the construct obtained
                                                               Evrogen                                                                                                                                           

  Transfected construct (*Homo sapiens*)   BIN1                Horizon Discovery ORFeome Collaboration Clones                   OHS5894-202501160                                                                Isoform 1

  Cell line\                               CHO-K1              Millipore Sigma                                                  Cat\# 85051005-1VL                                                               Chinese Hamster Ovary cell line
  (*Cricetulus griseus*)                                                                                                                                                                                         

  Transfected construct                    mKate2-Tau-mKate2   PMID:[25156556](https://www.ncbi.nlm.nih.gov/pubmed/25156556)                                                                                     

  Transfected construct                    Fyn-SH3-CBG         PMID:[25156556](https://www.ncbi.nlm.nih.gov/pubmed/25156556)                                                                                     BIN1-SH3 or LVGCC-β1-SH3 was cloned in replacing Fyn-SH3

  Transfected construct (*Homo sapiens*)   BIN1-SH3            IDT                                                              AAC28646.1                                                                       Codon optimized

  Transfected construct (*Homo sapiens*)   LVGCC-β1-SH3        IDT                                                              AAA35632.1                                                                       Codon optimized
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Primary neuron cultures {#s4-1}
-----------------------

Primary hippocampal culture protocols were adapted from [@bib70]. Briefly, hippocampal tissue from E19 Sprague Dawley albino rat (*Rattus norvegicus*) embryos was harvested on ice in 4°C Hibernate E (Life Technologies, A1247601) and digested with 20 units/mL papain (Worthington Biochemical Corporation, LK003178) for 10 min at 37°C. Neurons were then dissociated by manual trituration to a single-cell suspension in Neurobasal medium (Life Technologies, 21103049) supplemented with 1x B-27 (Gibco, 17504044), 2 mM L-Glutamine (Life Technologies, 25030081) and 10% premium select fetal bovine serum (Atlanta Biologicals, S11550). Neuronal plating conditions depended on the experiment, as follows.

### Multi electrode array cultures {#s4-1-1}

For 6-well multielectrode array recordings, neurons were plated at 100,000 per well in six-well MEA plates (ALA Scientific, ALAMEA-MEMMR5). For 48-well plate multielectrode array recordings, neurons were plated at 30,000 per well in 48-well MEA plates (Axion Biosystems, M768-tMEA-48B-5).

### Calcium imaging, electrophysiology, and immunocytochemistry cultures {#s4-1-2}

Neurons were plated at 50,000 neurons per well on 12 mm coverslips (Carolina Biological, 633029) in 24-well plates coated overnight at 4°C with 0.1 mg/mL Poly-D-Lysine (Sigma, P6407−10 × 5 MG) and 0.2 mg/mL laminin (Sigma, L2020-1MG) 24--48 hr prior to the neuron harvest, with the outer wells containing autoclaved ultrapure water (MilliQ filtered) to prevent evaporation.

### Immunoblotting {#s4-1-3}

Neurons were plated at 200,000 per well in six-well plates (Corning, 08-772-1B) and maintained in a 37°C humidified incubator with 5% CO~2~. 24 hr after plating, 75% of the medium was exchanged for serum-free Neurobasal supplemented with B-27 and L-Glutamine, with 5 μM cytosine β-D-arabinofuranoside (AraC, Sigma Aldrich, C6645) to inhibit glial proliferation. 50% medium changes were performed weekly with Neurobasal supplemented with B-27 and L-Glutamine until experiments were started at DIV 19--21.

BIN1 constructs and vectors {#s4-2}
---------------------------

A BIN1-mKate2 (GE Dharmacon, OHS5894-202501160) construct was developed to encode human BIN1 isoform 1 (593 AA, the major neuronal isoform) tagged with mKate2 (Evrogen, FP184, to allow for fluorescent visualization) at the C-terminus to allow for proper function of the N-terminal membrane-interacting BAR domain. A similar construct lacking the BAR domain (amino acids 32--273, BIN1-ΔBAR-mKate2) was produced as a BIN1 BAR domain deletion mutant. A construct encoding mKate2 only was used as a control. These constructs were then cloned into the CIGW vector (rAAV9-CBA-IRES-GFP-WPRE-rBG) ([@bib77]). Due to size limitations for efficient gene expression, the IRES-GFP was removed from the CIGW vector.

### Neuronal transduction {#s4-2-1}

BIN1-mKate2 and mKate2 vectors were packaged into rAAV2 at the University of Pennsylvania Vector Core (stock titers: AAV-BIN1-mKate2: 3.2e12 genomes/ml, AAV-mKate2: 9.69e12 genomes/ml; used titers: AAV-BIN1-mKate2 and AAV-mKate2: 1e10 genomes/ml, used MOI: AAV-BIN1-mKate2 and AAV-mKate2: 200,000). AAV vectors were used in MEA and electrophysiology experiments. Neuronal cultures were transduced on DIV 2.

### Neuronal transfection {#s4-2-2}

BIN1-mKate2, BIN1-ΔBAR-mKate2, and mKate2 vectors were used in transient transfections in calcium imaging experiments. Transfections were performed at DIV 14 using a calcium phosphate precipitation protocol adapted from [@bib24]. Briefly, Neurobasal medium was removed and kept until the last step of transfection used as conditioned Neurobasal medium. Neurons were washed for 1--1.5 hr in DMKY buffer containing 1 mM kynurenic acid, 0.9 mM NaOH, 0.5 mM HEPES, 10 MgCl~2~, plus phenol red 0.05%, pH 7.4. Then, 3.5 μg of the vectors were mixed with 120 mM CaCl~2~ in HBSS (Life Technologies, 14175095) containing 25 mM HEPES, 140 mM NaCl, and 0.750 mM Na~2~HPO~4~, pH 7.06, left for 20 min to precipitate the DNA, and applied to the primary hippocampal cultures for 30 min. The medium was then replaced with conditioned Neurobasal medium (Life Technologies, 21103049) and cultures were returned to the incubator until use.

Multielectrode array recordings {#s4-3}
-------------------------------

### Multi Channel Systems MEA {#s4-3-1}

MEA recording protocols were adapted from [@bib73]. Briefly, E19 rat hippocampal neurons were seeded to six-well MEAs containing nine extracellular recording electrodes and a ground electrode. Neurons were transduced with AAV expressing BIN1 or control constructs on DIV2. Transduced neurons had 50% medium changes with BrainPhys (StemcellTech, 05793) medium supplemented with N2A and SM1 at DIV 5 and 9 to promote maturation, then with supplemented Neurobasal (Life Technologies, 21103049) at DIV 12. 20 min MEA recordings were performed at DIV 12--13 in the temperature-controlled headstage at 37°C. Neuronal firing was amplified and acquired at 30 kHz, digitized, and further analyzed in MC_Rack (Multi Channel Systems). Data were filtered at 10 Hz and 10,000 Hz filters and thresholded to detect action potentials at each electrode. Detected action potentials were transferred to Offline Sorter (v. 4.0 Plexon) to differentiate multiple neurons detected with a single electrode using principal component analysis (PCA) of waveform properties. Offline Sorter automatically completes and plots PCA on waveforms for each electrode. Manual inspection of PCA, shape, inter-spike intervals, auto-correlograms, and cross-correlograms allowed us to distinguish between multiple units on a single electrode and to do per-neuron analyses. After waveforms were split into units, analysis of each unit's action potential frequency and burst firing was completed in NeuroExplorer (v. 5.0, Plexon) using the built-in Burst Analysis function, with Poisson burst surprise = 5. Next, firing rates and bursting analysis were performed in NeuroExplorer (v. 5.0 Plexon). Researchers were blinded to experimental conditions performed in all MEA analyses.

### Axion Biosciences MEA {#s4-3-2}

Single neuron electrophysiological activity was recorded using an Axion Maestero recording system as in [@bib72]. Briefly, neurons were plated on the 48-well MEA (Axion Biosystems, M768-tMEA-48B-5) with 16 extracellular recording electrodes and a ground electrode per well at a density of 30,000 neurons per well in Neurobasal medium (5 μL) with 10% FBS (Atlanta Biologicals, S11550) and placed in a 37°C incubator with 5% CO~2~. After allowing neurons to attach to the plate for 2 hr, 300 μL serum-free Neurobasal (Life Technologies, 21103049) was added. The next day, AraC was added as with other experiments and a 50% medium change with BrainPhys (Stemcell Technologies Inc, 05790) supplemented with SM1 and L-glutamine was done at DIV 5. At DIV 6, neurons were treated with ASO to reduce Tau protein levels. At DIV 9, a 50% medium change was completed with supplemented BrainPhys, followed by a 50% medium change with supplemented Neurobasal at DIV 12. At DIV 13, neurons were recorded using Axion AxIS software for 15 min. Electrical activity was measured by an interface board at 12.5 kHz, digitized, and transmitted to an external computer for data acquisition and analysis in Axion AxIS Navigator software (Axion Biosystems). All data were filtered using dual 0.01 Hz (high pass) and 5,000 Hz (low-pass) Butterworth filters. Action potential thresholds were set automatically using an adaptive threshold for each electrode (\>6 standard deviations from the electrode's mean signal). Neuronal waveforms collected in Axion AxIS Navigator were exported to Offline Sorter (v. 4.0 Plexon). Offline Sorter automatically completes and plots PCA on waveforms for each electrode. Manual inspection of PCA, shape, inter-spike intervals, auto-correlograms, and cross-correlograms allowed us to distinguish between multiple units on a single electrode and to do per-neuron analyses. After waveforms were split into units, analysis of each unit's action potential frequency and burst firing was completed in NeuroExplorer (v. 5.0, Plexon) using the built-in Burst Analysis function, with Poisson burst surprise = 5. Next, firing rates and bursting analysis were performed in NeuroExplorer (v. 5.0 Plexon). Researchers were blinded to experimental conditions performed in all MEA analyses.

Antisense oligonucleotide application {#s4-4}
-------------------------------------

Tau anti-sense oligonucleotide (ASO) sequences were adapted from [@bib20] and produced by Integrated DNA Technology (Tau ASO: 5-ATCACTGATTTTGAAGTCCC-3, Nontargeting control ASO: 5-CCTTCCCTGAAGGTTCCTCC-3). ASOs were dissolved to 100 μM in 10 mM Tris with 0.1 mM EDTA and stored at −20°C until use. At DIV 6, one week before testing for both MEA experiments and PLA, neurons were treated with ASO to a final concentration of 1 μM.

Calcium imaging {#s4-5}
---------------

Calcium imaging was adapted from [@bib47]. Briefly, rat primary hippocampal neurons (DIV 14) were transfected (see Neuronal transfection section) with the genetically engineered calcium sensor GCaMP6f (gift from Dr. Alain Buisson, originally developed by Douglas Kim and GENIE Project, Addgene plasmid \#40755, [@bib13]). At DIV 21, the neurons were incubated for 15 min at room temperature in HEPES and bicarbonate buffered saline solution (HBBSS) containing 116 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl~2~, 0.8 mM MgSO~4~, 1.3 mM NaH~2~PO~4~, 12 mM HEPES, 5.5 mM glucose, 25 mM bicarbonate and 10 μM glycine at pH 7.45. Neurons that were transfected with mKate2 or BIN1-mKate2 vectors (see BIN1 constructs and vectors section) were recorded for 8 min. Experiments were performed at room temperature with continuous perfusion at 2 ml/min with a peristaltic pump, on the stage of a Nikon A1R Confocal (Nikon, TE2000) inverted microscope equipped with a 100 W mercury lamp and oil-immersion Nikon 40x objective with 1.3 numerical aperture (Nikon, Tokyo, Japan). GCaMP6f (excitation: 340/380 nm, emission: 510 nm) ratio images were acquired at 8 Hz with a digital camera (Princeton Instruments, Trenton, NJ) using Metafluor 6.3 software (Universal Imaging Corporation, West Chester, PA, USA). Fluorescence ratios (340/380 nm) were converted to intracellular Ca^2+^ concentration using the following formula:$$\lbrack Ca^{2 +}\rbrack_{i} = K_{d}(\frac{R - R_{min}}{R_{max} - R})(\frac{F_{0}}{F_{s}})$$where *R* is the measured ratio of 340/380 fluorescence, *R*~min~ is the ratio measured in a Ca^2+^-free solution, *R*~max~ is the ratio measured in a saturated Ca^2+^ solution, *K*~d~ = 135 nM (the dissociation constant for GCaMP6f), and *F*~0~ and *F*~s~ are the fluorescence intensities measured at 380 nm, respectively, in a Ca^2+^-free solution or in a saturated Ca^2+^ solution.

Electrophysiology {#s4-6}
-----------------

All electrophysiological recordings were performed in primary hippocampal neuronal cultures after 19--21 DIV. Whole-cell patch-clamp recordings were made from visually identified pyramidal neurons. Recorded signals were amplified with a MultiClamp 700B amplifier (Molecular Devices), filtered at 5 kHz, and sampled at 10 kHz with Digidata 1550A (Molecular Devices). Recordings were acquired using pClamp (v.10) and analyzed using Clampfit (Molecular Devices). Patch pipettes had a resistance of 2.5--5 MΩ when filled with the internal solution required for the experiments described below. All recordings were performed at room temperature (21--23°C). Internal solution included 120 mM Cs-gluconate, 0.6 mM EGTA, 2.8 mM NaCl, 5 mM MgCl~2~, 2 mM ATP, 0.3 mM GTP, 20 mM HEPES, and 5.0 mM QX-314. External solution included 119 mM NaCl, 2.5 mM KCl, 1.3 mM MgSO~4~, 2.5 mM CaCl~2~, 1 mM NaH~2~PO~4~, 26 mM NaHCO~3~, 11 mM glucose (pH 7.3). Voltage-clamp recordings to measure sEPSCs were performed from cultured neurons by whole-cell patch-clamp holding the neurons at --70 mV with 100 µM picrotoxin (GABA~A~R antagonist, Tocris, 11--281 G) in the bath solution. Voltage-clamp recordings to measure sIPSCs were performed from cultured neurons by whole-cell patch-clamp holding the neurons at 0 mV in 10 µM DNQX (AMPAR antagonist, Sigma, D0540-25MG), 100 µM APV (NMDAR antagonist, Tocris, 01-055-0), and 10 µM nifedipine (L-type VGCC antagonist, Sigma, N7634-25G) to enrich for sIPSCs from spontaneously active interneurons rather than from interneuron-driven by excitatory transmission.

Immunocytochemistry (ICC) and NeuN quantification {#s4-7}
-------------------------------------------------

ICC was adapted from [@bib70]. Briefly, primary neurons on coverslips were fixed with 4% PFA and 4% sucrose in 1x PBS. Coverslips were permeabilized with 0.25% Triton X-100 in 1x PBS for 10 min at room temperature then blocked for one hour in 5% FBS in 1x PBS. Primary antibody for NeuN (abcam, ab104225, 1:500), GAD67 (Millipore Sigma, MAB5406, 1:500), BIN1 (Santa Cruz, sc-30099, 1:500), or LVGCC-β1 (Abcam, S7-18, 1:1,000) in 1% FBS in 1x PBS was applied overnight at 4°C. Coverslips were then washed 3 × 5 min in 1x PBS, then incubated in Alexa Fluor fluorescent antibodies (1:1,000) in 1% FBS in 1x PBS for 1 hr at room temperature. Coverslips were washed 3 × 5 min in 1x PBS, then mounted in Prolong Diamond. For neuron quantification, 10 × 10 images at 20x were taken with an epiflourescent microscope and automatically stitched together using Nikon NIS-Elements. NeuN images were thresholded in ImageJ, then quantified using ImageJ (v. 2.0.0-rc-69/1.52 p) particle analyzer.

Proximity Ligation Assay (PLA) {#s4-8}
------------------------------

PLA was adapted from [@bib70]. Briefly, neurons on coverslips were fixed and permeabilized as with ICC, then were incubated overnight with primary antibodies for BIN1 (Santa Cruz, sc-30099, 1:500) and LVGCC-β1 (Abcam, S7-18, 1:1,000) overnight at 4°C, then PLA was performed using the Duolink In Situ Fluorescence kit (Sigma, DUO92004-100RXN). After PLA, coverslips were incubated with secondary antibody to view BIN1 and mounted with Duolink In Situ Mounting Medium with DAPI. Fluorescent images were taken using an epifluorescence microscope at 60x with four channels: DAPI (nuclei), FITC (PLA), and TRITC (mKate2). 7--9 images per slide were obtained and analyzed using ImageJ (v. 2.0.0-rc-69/1.52 p). PLA puncta were quantified using ImageJ particle analyzer, and the average number of puncta per field of view (FOV) or each coverslip was used for analysis.

Bioluminescence Resonance Energy Transfer (BRET) {#s4-9}
------------------------------------------------

BRET was conducted as described in [@bib16]. Codon-optimized human BIN1-SH3 or LVGCC-β1-SH3 domains were fused on the C-terminus to click beetle green (CBG) luciferase (Promega, E1461) replacing the Fyn-SH3 in the previously described donor construct. Tau tagged at each terminus with mKate2 (Evrogen, FP184) served as the acceptor. Chinese hamster ovary (CHO) cells (Sigma, 85051005-1VL) obtained from ECACC (Lot number 12G006) were authenticated using DNA Fingerprinting and DNA bar-coding sequencing and tested negative for mycoplasma contamination using PCR, a Vero indicator cell line, and Hoechst 33258 fluorescent detection system (Certificate of Analysis test number 47856). CHO cells were plated in 24-well opaque white plates (Promega, 6005168) using the manufacturer's instructions and transfected with donor and acceptor constructs using Fugene. Forty-eight hours later, fluorescence was read by excitation with a 530/25 nm filter and emission with a 645/40 nm filter on a Synergy2 (BioTek) to control for the concentration of the donor. Immediately after fluorescence measurement, D-luciferin (Promega, E1605) was added to a final concentration of 200 µM to each well. Two to 4 hr later, after the signal had stabilized, plates were read with 645/40 nm filter. Measured BRET fluorescence was normalized to mKate2 fluorescence.

Co-immunoprecipitation {#s4-10}
----------------------

Mouse hemibrains were finely chopped while frozen, then thawed on ice in PBS plus protease inhibitors (Fisher PI-78439), phosphatase inhibitors (Sigma-Aldrich, P5726), and 1 mM of the cell-permeable cross-linker DSP (Fisher, PI-22585). Hemibrains were then homogenized for 15 s using a hand-held Kontes Pellet Pestle homogenizer, then pipetted up and down 20x to obtain a smooth lysate. Lysates were spun 2 × 10 min at 800 x *g*, then cleared lysates were incubated for 15 min at 4°C on an end-over-end rotator. Next, lysates were brought to 100 mM Tris to inactivate DSP and incubated for another 15 min at 4°C on an end-over-end rotator. Samples were then diluted 1:1 with a mild co-IP buffer: 10 mM Tris (pH 7.5), 10 mM NaCl, 3 mM MgCl~2~, 1 mM EGTA, and 0.05% Nonidet P-40, a mild lysis buffer previously shown to be amenable to co-IP experiment ([@bib23]). At this point, an input fraction was set aside before adding IP antibody to the lysate, with 5 µg of antibody used in each case. Lysate/antibody mixtures were incubated overnight on an end-over-end rotator. Next, 50 uL of Protein G--coated magnetic beads (Life Technologies, 10004D) were added and incubated for 8 hr at 4°C on an end-over-end rotator. Next, non-interacting lysate was removed, the bead/antibody/antigen complex was washed, then protein was eluted with 50 mM Glycine (pH 2.8) and neutralized with 1 M Tris, reduced with β-Mercaptoethanol and an 80°C incubation for 10 min, then cooled and probed by immunoblotting.

Immunoblots {#s4-11}
-----------

5 µg of immunoprecipitated samples were loaded and separated on 4--12% NuPage acrylamide gels (Invitrogen) with NuPage MOPS running buffer for 2 hr at 110 V. Next, proteins were transferred to Immobilon-FL PVDF membranes (Millipore) using the NuPage transfer buffer transfer system (Invitrogen) overnight. The membrane was blocked in LI-COR Odyssey blocking buffer (LI-COR, 927--40000) for 1 hr at room temperature and incubated with the appropriate primary antibody. After primary antibody treatment, membranes were washed three times in tris-buffered saline with 0.1% Tween (TBS-T), followed by incubation for 1 hr with Alexa Fluor 700-- or 800--conjugated goat antibodies specific for mouse immunoglobulin G (1:20,000, LI-COR). Membranes were then washed three times in TBST-T, followed by a single wash in TBS, imaged on the LI-COR Odyssey fluorescence imaging system, and quantified using LI-COR Image Studio (v. 5.2.5).

Animals {#s4-12}
-------

All breeding and experimental procedures were approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee and follow the guidelines by the National Institutes of Health. Male and female Tau^+/--^ mice lacking exon 1 of MAPT gene were bred to obtain Tau^--/--^ mice with littermate Tau^+/+^ controls. Mice were maintained under standard laboratory conditions (12 hr light/dark cycle, 50% humidity, Harlan 2916 diet, and water ad libitum). Genotype was verified by standard PCR protocol.

Statistics {#s4-13}
----------

Statistical distribution of data varied widely between data sets in this study, so we analyzed each data set for normality and analyzed using either parametric or non-parametric tests accordingly. The specific test used is indicated in the figure legend in each case. All statistical tests were performed with Prism 8 (GraphPad, v. 8.4.0).
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Additional files {#s6}
================

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 6; high throughput raw electrophysiologic recordings of neuronal activity using Axion Biosciences Maesto are deposited on Dryad at <https://doi.org/10.5061/dryad.rbnzs7h8z>. Brief Analysis used is described in the methods section; in-depth analysis description is publicly available at <https://www.axionbiosystems.com/products/software/neural-module>.

The following dataset was generated:

VoskobiynykYRothJRCochranJNRushTCarulloNVNMesinaJSWaqasMVollmerRMDayJJMcMahonLLRobersonED2020Data from: Alzheimer's disease risk gene BIN1 induces Tau-dependent network hyperexcitabilityDryad Digital Repository10.5061/dryad.rbnzs7h8z
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Genetic studies clearly indicate that BIN1 modifies risk for developing Alzheimer\'s disease, but the mechanisms underlying this biology are poorly understood. In this study, Voskobiynyk et al. performed a rigorous set of studies that places BIN1 squarely in the tau-associated network hyperexcitability problem, with a mechanistic link via a direct interaction of BIN1 with L-type voltage-gated calcium channels (LVGCCs). This provides a much deeper understanding of not only normal BIN1 function, but how it may contribute to Alzheimer\'s disease pathogenesis.

**Decision letter after peer review:**

Thank you for submitting your article \"Alzheimer\'s disease risk gene BIN1 induces Tau-dependent network hyperexcitability\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Miranda Reed (Reviewer \#1); Brian Kraemer (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

In this manuscript, Voskobiynyk et al. describe a new function for BIN1 related to network hyperexcitability that is directly modulated by the presence of tau. BIN1 is one of many Alzheimer\'s risk genes for which we have very little functional data. Using multielectrode arrays and calcium imaging in primary rat neurons, these authors demonstrate that human BIN1 expression induces network hyperexcitability and that these readouts are modulated by tau expression, likely via interactions with L-type voltage gated calcium channels. This data provides important functional understanding of how BIN1 influences Alzheimer\'s risk and sets the stage for future functional studies in animal models.

Essential revisions:

The invited reviewers and the reviewing editor unanimously agree that this study reveals important new insights into BIN1 function, and that the data were designed and carried out rigorously. A few additional points of clarification are needed that would greatly strengthen the manuscript.

1\) Please include data regarding the excitatory/inhibitory balance for Figure 2 if available. Related to these conclusions, discussing the reversal potential how sIPSCs were measured at 0 mV is needed to better put these electrophysiological aspects in perspective.

2\) It is also necessary to provide additional details on levels of BIN1 in DIV12 vs. DIV19 neurons (and state of neuronal health at both time points)

10.7554/eLife.57354.sa2

Author response

> Essential revisions:
>
> The invited reviewers and the reviewing editor unanimously agree that this study reveals important new insights into BIN1 function, and that the data were designed and carried out rigorously. A few additional points of clarification are needed that would greatly strengthen the manuscript.
>
> 1\) Please include data regarding the excitatory/inhibitory balance for Figure 2 if available.

This is an interesting question that is a bit challenging to answer directly using dissociated neurons as we did in this study. The best and most direct way to measure excitatory/inhibitory (E/I) balance is by stimulating to evoke a monosynaptic EPSC followed by a disynaptic IPSC, as occurs in intact CA3-CA1 circuits in hippocampal slices, and then calculating the evoked E/I ratio (see, for example, (Stewart et al., 2020). Because dissociated hippocampal neuron cultures in vitro lack the anatomic pattern of synaptic connectivity in slices, it is not possible to do this in our system. Furthermore, recording sEPSCs and sIPSCs simultaneously in the same cell requires voltage clamping the neuron at a holding potential that allows sEPSCs to be electrically isolated from sIPSCs (i.e., at which EPSCs are inward currents and IPSCs are outward currents). Under our recording conditions, a patched neuron would have to be held at around --30 mV, a potential at which the driving force would be \~30 mV for both EPSCs and IPSCs, since sEPSC~rev~ ≈ 0mV and IPSC~rev~ ≈ --60 mV. We did not take this approach with our recordings due to concern that the small driving force would yield synaptic events too small to be easily resolved during analysis (see answer to next question).

An alternative approach to answering this question is to indirectly assess E/I balance mathematically by calculating the ratios of sEPSCs to sIPSCs frequency and amplitude ([Author response table 1](#resptable1){ref-type="table"}). This is less ideal than the direct approach, as the sEPSCs and sIPSCs were not recorded in the same cells so formal statistical comparisons are not possible. But consistent with our findings of BIN-induced network hyperexcitability, higher BIN1 levels increased the E/I ratio of both frequency (from 0.24 ± 0.71 to 0.47 ± 4.30) and amplitude (from 0.37 ± 0.27 to 0.43 ± 0.97).

###### Calculated E/I ratios of spontaneous postsynaptic current frequencies and amplitudes.

              mKate2 Frequency, mean ±SEM   BIN1-mKate2 Frequency, mean ±SEM   mKate2 Amplitude, mean ±SEM   BIN1-mKate2 Amplitude, mean ±SEM
  ----------- ----------------------------- ---------------------------------- ----------------------------- ----------------------------------
  sEPSCs      1.65 ± 26.59 Hz               3.53 ± 65.58 Hz                    31.15 ± 0.40 pA               29.02 ± 0.53 pA
  sIPSCs      6.82 ± 37.61 Hz               7.57 ± 15.25 Hz                    83.07 ± 1.49 pA               67.73 ± 0.55 pA
  E/I ratio   0.24 ± 0.71                   0.47 ± 4.30                        0.37 ± 0.27                   0.43 ± 0.97

> Related to these conclusions, discussing the reversal potential how sIPSCs were measured at 0 mV is needed to better put these electrophysiological aspects in perspective.

To assess whether higher BIN1 expression modulates sIPSCs, we performed whole-cell patch-clamp recordings from visually identified pyramidal neurons using the identical internal solution that we used for measuring sEPSCs (Cs-gluconate internal solution), which has a chloride reversal potential (E~Cl~^-^ = --60 mV) near the resting membrane potential as is typical for hippocampal neurons. Therefore, to ensure that the driving force was large enough for us to easily resolve sIPSCs, patched cells were voltage clamped at 0 mV and recorded in the presence of inhibitors of AMPARs (10 µM DNQX) and NMDARs (100 µM APV). Thus, sIPSCs were both pharmacologically and electrically isolated from sEPSCs because sEPSCs reverse at 0 mV. In addition, an L-type VGCC antagonist (10 µM nifedipine) was employed to prevent contamination from active currents. These recording conditions are often used to enrich for sIPSCs from spontaneously active interneurons rather than from interneurons whose excitation was driven by excitatory transmission (Salin and Prince, 1996; Kotak and Sanes, 2000, 2014).

> 2\) It is also necessary to provide additional details on levels of BIN1 in DIV12 vs. DIV19 neurons (and state of neuronal health at both time points).

We agree that these are important points and have added additional data to Figure 1 to address them (new Figure 1A-C). We demonstrated in the original submission that there were no significant differences in neuronal survival at DIV12 in any of the groups (original Figure 1H, I, which is now Figure 1D, E). For the new data, we grew neurons on coverslips, transduced with AAVs as before, then fixed and performed ICC to measure BIN1 levels and to verify neuronal health by evaluating structural integrity with Tau staining. BIN1 levels were \~8-9 times higher in neurons with AAV-BIN1-mKate2 than in untransduced or AAV-mKate2 neurons, and BIN1 levels were consistent from DIV 15--27. Through at least DIV 27, well past our experimental timepoints, neurons were morphologically normal without any evidence of adverse effects, as demonstrated with Tau ICC.

As a functional assessment, we used whole-cell current clamp to record the resting membrane potential (RMP) and input resistance (R~in~) of neurons at DIV 19, which also indicated no detrimental effects of AAV-BIN1-mKate2 (Table 1). RMP and R~in~ were similar across three groups (mean ± SEM) and consistent with healthy cultured neurons (Meadows et al., 2016).

Altogether, these results demonstrate that BIN1 levels were consistently increased over time after transfection and that the neurons in all groups were healthy well past our experimental timepoints.
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